Retatrutide: A Research Guide to the GLP-1 / GIP / Glucagon Triple Agonist

Retatrutide is a synthetic peptide that activates three incretin-axis receptors in a single molecule: GLP-1, GIP, and glucagon. It is the first triple agonist to reach late-stage research with consistent, publishable results across multiple clinical trial sites.

What 'triple agonist' actually means

Most well-known research peptides in this class hit one or two receptors:

• Semaglutide — single agonist (GLP-1 only)
• Tirzepatide — dual agonist (GLP-1 + GIP)
• Retatrutide — triple agonist (GLP-1 + GIP + glucagon)

Adding glucagon receptor activity is the meaningful difference. Glucagon agonism in this context contributes to increased energy expenditure and hepatic fat mobilization in published research, which is the part single- and dual-agonists do not directly drive.

What the literature shows

Published phase-2 research and presentations show retatrutide producing larger composition shifts than semaglutide or tirzepatide at comparable trial durations. Effects observed in the literature include:

• Substantial reductions in body weight and visceral adiposity
• Improvements in glycemic markers (HbA1c, fasting glucose)
• Reductions in hepatic fat content
• Dose-dependent response curves with diminishing returns above ~12 mg/week in some cohorts

Researchers consistently report titration up from a low starting dose to manage early GI tolerability.

Common research dose ranges

Reported research ranges typically fall between 1 mg and 12 mg per week, administered subcutaneously, with most protocols titrating gradually over 4–8 weeks.

A common research titration schedule observed in published protocols:

Phase	Weekly dose	Duration
Initiation	1 mg	2–4 weeks
Step 1	2 mg	2–4 weeks
Step 2	4 mg	2–4 weeks
Step 3	6 mg	maintenance

Higher steps (8–12 mg) appear in some trial arms but with proportionally more GI events.

Frequency and dose figures shown above are reference figures observed in published peptide research literature. They are not medical advice or recommendations for human use.

Reconstitution and storage

Lyophilized retatrutide is typically reconstituted with bacteriostatic water. With a 10 mg vial + 2 mL BAC water, the concentration is 5 mg/mL (5,000 mcg/mL). At a 2 mg research dose this is 0.4 mL, or 40 units on a U-100 insulin syringe.

Reconstituted vials are usually refrigerated at 2–8 °C and considered stable for 4–6 weeks per common research storage references.

How it differs from tirzepatide and semaglutide

The added glucagon arm is the key differentiator. In head-to-head research presentations:

• Semaglutide focuses on appetite suppression and insulin sensitization (GLP-1 axis).
• Tirzepatide adds GIP, broadening glucose-handling effects.
• Retatrutide adds glucagon, which contributes to fat mobilization and energy expenditure beyond what GLP-1/GIP alone produce.

This makes retatrutide a focal point in current metabolic peptide research.

Reconstitution example

If you're running our Dose & Reconstitution Calculator, select Retatrutide 10 mg, choose your dose, and the volume + insulin syringe units update automatically based on the BAC water amount you reconstituted with.